Keyword: Hikma Pharmaceuticals
Joining other drug companies announcing slim-down efforts in recent months, Astellas is shedding 600 jobs in Japan in R&D and sales and marketing.
Novartis’ prospects for launching a copy of GlaxoSmithKline’s Advair this year just went from highly unlikely to not happening.
Hikma Pharmaceuticals is changing up more than just its CEO. It's rebranded, with a modern logo and visual identity.
Hikma has already cut 200 jobs since picking up generics business Roxane Labs from Boehringer Ingelheim. But more layoffs are coming.
GlaxoSmithKline just keeps racking up the victories in the generic Advair department, this time with a yearslong delay to Hikma's copy.
Former Teva Generics CEO Siggi Olafsson is back in the copycat game—this time, as the new CEO of Jordan’s Hikma Pharmaceuticals.
Those waiting for Hikma and Vectura’s copy of GlaxoSmithKline blockbuster Advair may be waiting awhile.
Hikma's U.S. unit West-Ward boosted prices as much as fourfold on a half-dozen generic meds, most of them liquid formulations.
The FDA has already nixed two generics of GSK's Advair. But Novartis’ Sandoz is hoping its version can be the one to turn the tide.
GlaxoSmithKline dodged yet another generic Advair bullet. Hikma and Vectura's knockoff was struck down at FDA Thursday, and an approval later this year is a long shot, the companies say.